What is eScreen?
Founded in 1998 and headquartered in Kansas City, Missouri, eScreen, Inc. specializes in comprehensive drug testing services. The company offers a range of testing methods, including urine, oral fluid, and hair analysis, complemented by its proprietary Quantisal Lab Oral Fluid Collection Device. eScreen serves a critical role in workplace safety and compliance by providing reliable and efficient screening solutions for employers across various sectors. Its established presence in the market indicates a mature operational framework and a deep understanding of regulatory requirements and client needs in the drug testing domain.
How much funding has eScreen raised?
eScreen has raised a total of $8M across 1 funding round:
Series B
$8M
Series B (2008): $8M with participation from The Carlyle Group
Key Investors in eScreen
The Carlyle Group
The Carlyle Group is a global investment firm with a strong focus on private equity, venture capital, and growth capital. Their extensive experience in managing diverse funds and their worldwide presence suggest a strategic approach to investing in established companies with significant growth potential, aligning with eScreen's market position.
What's next for eScreen?
The recent major strategic investment in eScreen signals a phase of accelerated development and market penetration. With substantial enterprise-level backing, the company is well-positioned to enhance its technological offerings, expand its service reach, and potentially explore new verticals within the broader health and safety technology sector. This capital injection is expected to fuel innovation in its diagnostic tools and collection devices, reinforcing its competitive edge and supporting its long-term strategic objectives. The focus will likely remain on leveraging its established infrastructure to capture greater market share and solidify its leadership in drug screening solutions.
See full eScreen company page
